Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 10/20 | 0.66 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | GALR2 | O43603 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637714 | 0.93 | ROCK2 (0.56) | ROCK2ROCK1MEN1NPC1ALDH1A1 | |
| SCHEMBL16637772 | 0.86 | ROCK2 (0.69) | ROCK2ROCK1CDK2 | |
| SCHEMBL16637613 | 0.86 | ROCK2 (0.49) | ROCK2ROCK1MEN1NPC1ALDH1A1 | |
| SCHEMBL16637609 | 0.80 | ROCK2 (1.00) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL16637702 | 0.79 | ROCK2 (0.44) | ROCK2ROCK1MEN1NPC1ALDH1A1 | |
| SCHEMBL17164484 | 0.78 | ROCK2 (0.69) | ROCK2ROCK1 | |
| SCHEMBL16637715 | 0.72 | ROCK2 (0.88) | ROCK2ROCK1MEN1NPC1ALDH1A1 | |
| SCHEMBL16637498 | 0.72 | NCF1 (0.50) | ROCK1NPC1RAB9AEGFRCYP3A4 | |
| SCHEMBL4514604 | 0.70 | CYP17A1 (0.76) | NPC1RAB9APDGFRBPDGFRACYP17A1 | |
| SCHEMBL28776986 | 0.70 | ROCK2 (0.66) | ROCK2ROCK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10125144-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2018-11-13 | — | — | US | claimed |
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3055301-B1 | (2-(5-ISOINDOLIN-2-YL)PYRIMIDIN-4-YL)-AMINE DERIVATIVES AS RHO KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | KADMON CORP LLC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10125144-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170112832-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC | 2017-04-27 | — | — | US | disclosed |
| EP-3055301-A1 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015157556-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015054317-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | ROCK2 1/4885ROCK1 4/4885MEN1 3775/4885 |
| US-10125144-B2 | Rho kinase inhibitors | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885MEN1 776/4885 |
| US-20170112832-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885MEN1 3586/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | ROCK2 1/4885ROCK1 2/4885MEN1 3628/4885 |
| US-11311541-B2 | Treatment of GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885MEN1 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.